Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age. The study aims to assess adverse events and the effectiveness of atogepant in preventing migraines in adolescents aged 12 to 17. This research is significant as it explores a new potential treatment for a younger demographic suffering from chronic migraines.
The study tests the drug atogepant, an oral tablet already approved for adult migraine prevention in the US and Europe, against a placebo. The goal is to determine its safety and efficacy in adolescents.
This interventional study employs a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are unaware of who receives the actual drug or placebo. The primary purpose is treatment-focused.
The study began on February 13, 2025, with an estimated primary completion date not yet specified. The latest update was submitted on June 30, 2025. These dates are crucial as they mark the progress and timeline of the study, which is currently recruiting participants.
For investors, this study could impact AbbVie’s stock performance positively if atogepant proves effective in this new age group, potentially expanding its market. The pharmaceutical landscape for migraine treatments is competitive, with companies continuously seeking innovative solutions.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.